B. Riley Securities Maintains Buy on Elicio Therapeutics, Lowers Price Target to $8
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
B. Riley Securities analyst Mayank Mamtani maintains Elicio Therapeutics (NASDAQ:ELTX) with a Buy and lowers the price target from $27 to $8.
B. Riley Securities analyst Mayank Mamtani maintains Elicio Therapeutics (NASDAQ:ELTX) with a Buy and lowers the price target from $27 to $8.